027 Cicatricial Alopecia: Consensus Conference Guidelines

Olsen EA,1 Bergfeld W,2 Cotsarelis G,3 Price V,4 Shapiro J,5 Sinclair R,6 Solomon A,7 Sperling L,8 Stenn K,9 Whiting D,10 and the Cicatricial Alopecia Research Group 1Duke University Medical Center, Durham, NC; 2Cleveland Clinic, Cleveland, Ohio; 3University of Pennsylvania, Philadelphia, PA; 4University of California- San Francisco, San Francisco, CA; 5University of British Columbia, Vancouver, BC; 6University of Melborne, Melborne, Australia; 7Emory University, Atlanta, GA; 8Armed Services Institute, Bethesda, MD; 9Skin Biology Research, Johnson and Johnson, Skillman, NJ; 10Baylor Hair Institute, Dallas, TX

Advances in the understanding and treatment of cicatricial alopecia have been hampered by difficulties in making an early diagnosis, terminology that currently is subject to widely varied interpretation, lack of uniformity in selection and timing of biopsy sites and pathologic evaluation, lack of easily reproducible endpoints to use to evaluate different therapies and lack of information on potentially confounding hair care factors. A meeting was held February 10-11, 2001 at Duke University Medical Center to discuss the above. Consensus recommendations for 1) clinical evaluation, 2) biopsy and pathologic evaluation, and 3) therapeutic endpoints were made as well as a working pathologic classification based on type of inflammatory infiltrate seen histologically and will be presented in further detail.